金刚烷胺与莫达非尼作为卒中后神经刺激剂:系统综述
该系统综述检索MEDLINE与EMBASE至2020年2月1日,纳入10篇金刚烷胺文献(121例患者)和12篇莫达非尼文献(120例患者),均为卒中后成人。金刚烷胺起始于卒中后39(16,385)天,最常见初始剂量100 mg每日一次或两次(范围100-200 mg/天),最终日剂量200(188,200)mg/天;莫达非尼起始于卒中后170(17,496)天,初始与最终日剂量分别为100(100,350)mg/天和200(100,350)mg/天。金刚烷胺最常见适应症为意识障碍(3/10篇,30%),莫达非尼为疲劳(5/12篇,42%)。至少一项临床有效性指标阳性反应见于70%金刚烷胺文献和83%莫达非尼文献。仅各1篇研究急性住院或ICU患者(金刚烷胺10%,n=5;莫达非尼8%,n=21),均为随机研究,分别显示神经认知功能和疲劳改善。约50%文献报告潜在药物不良反应,最常见金刚烷胺视觉幻觉(2%患者)、莫达非尼头晕(5%患者)和眼干或口干(5%患者)。作者认为两者可能改善卒中后认知与功能恢复,但需更高质量数据确认,尤其在急性期。
要点
- 金刚烷胺最常见初始剂量100 mg每日一次或两次(范围100-200 mg/天),最终日剂量200(188,200)mg/天,起始于卒中后39(16,385)天。
- 莫达非尼初始日剂量100(100,350)mg/天,最终日剂量200(100,350)mg/天,起始于卒中后170(17,496)天。
- 金刚烷胺最常见适应症为意识障碍(3/10篇,30%),莫达非尼为疲劳(5/12篇,42%)。
- 至少一项临床有效性指标阳性反应见于70%金刚烷胺文献和83%莫达非尼文献,但有效性指标异质性大(40种指标、141个域),未行定量分析。
- 仅各1篇研究急性住院或ICU患者(金刚烷胺10%,n=5;莫达非尼8%,n=21),均为随机研究,分别显示神经认知功能和疲劳改善。
适用人群与场景
- 年龄≥18岁的卒中后患者。
- 仅各1篇研究纳入急性住院或ICU患者(金刚烷胺10%,n=5;莫达非尼8%,n=21)。
处置流程与药物剂量
- 金刚烷胺:起始于卒中后39(16,385)天,最常见初始剂量100 mg每日一次或两次(范围100-200 mg/天),最终日剂量200(188,200)mg/天。
- 莫达非尼:起始于卒中后170(17,496)天,初始日剂量100(100,350)mg/天,最终日剂量200(100,350)mg/天。
研究设计与关键结果
- 系统综述纳入10篇金刚烷胺文献(n=121例患者)和12篇莫达非尼文献(n=120例患者),共40种临床有效性指标(每研究1.8种)和141个域(每研究6.4个)。
- 至少一项临床有效性指标阳性反应见于70%金刚烷胺文献和83%莫达非尼文献。
- 仅各1篇研究急性住院或ICU患者:金刚烷胺10%(n=5例患者),莫达非尼8%(n=21例患者),均为随机研究,分别显示神经认知功能和疲劳改善。
- 约50%文献报告潜在药物不良反应,最常见金刚烷胺视觉幻觉(2%患者)、莫达非尼头晕(5%患者)和眼干或口干(5%患者)。
证据类型、等级与局限
- 证据类型:系统综述,遵循PRISMA指南,因临床有效性指标异质性未行定量分析,描述性数据以数量(百分比)或中位数(四分位距)呈现。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为金刚烷胺和莫达非尼可能改善卒中后认知与功能恢复,但需更高质量数据确认此结论,尤其在急性期。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Amantadine and modafinil are neurostimulants that may improve cognitive and functional recovery post-stroke, but the existing study results vary, and no comprehensive review has been published. This systematic review describes amantadine and modafinil administration practices post-stroke, evaluates timing and impact on clinical effectiveness measures, and identifies the incidence of potential adverse drug effects. A librarian-assisted search of the MEDLINE (PubMed) and EMBASE databases identified all English-language publications with "amantadine" or "modafinil" in the title or abstract from inception through February 1, 2020. Publications meeting predefined Patient, Intervention, Comparator, Outcome (PICO) criteria were included: Patients (≥ 18 years of age post-stroke); Intervention (amantadine or modafinil administration); Comparison (pretreatment baseline or control group); Outcomes (cognitive or functional outcome). Amantadine and modafinil administration practices, cognitive and functional outcomes, and incidence of potential adverse drug effects were collected following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidance. Quantitative analyses were not performed due to heterogeneity in the clinical effectiveness measures; descriptive data are presented as number (percent) or median (interquartile range). Of 12,620 publications initially identified, 10 amantadine publications (n = 121 patients) and 12 modafinil publications (n = 120 patients) were included. Amantadine was initiated 39 (16, 385) days post-stroke, with most common initial doses of 100 mg once or twice daily (range 100-200 mg/day), and final daily dose of 200 (188, 200) mg/day. Modafinil was initiated 170 (17, 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350) mg/day, respectively. The most common indication was consciousness disorders for amantadine (n = 3/10 publications; 30%) and fatigue for modafinil (n = 5/12; 42%). Forty unique clinical effectiveness measures (1.8 per study) with 141 domains (6.4 per study) were described across all studies. A positive response in at least one clinical effectiveness measure was reported in 70% of amantadine publications and 83% of modafinil publications. Only one publication each for amantadine (10%; n = 5 patients) and modafinil (8%; n = 21 patients) studied acutely hospitalized or ICU patients; both were randomized studies showing improvements in neurocognitive function for amantadine and fatigue for modafinil. Potential adverse drug effects were reported in approximately 50% of publications, most commonly visual hallucinations with amantadine (2% of patients) and dizziness (5% of patients) and dry eyes or mouth (5% of patients). Amantadine and modafinil may improve cognitive and functional recovery post-stroke, but higher-quality data are needed to confirm this conclusion, especially in the acute care setting.
参考来源
- Gagnon DJ, Leclerc AM, Riker RR, et al. Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review. Neurocrit Care. 2020. PMID: 32394130. doi:10.1007/s12028-020-00977-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。